ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
1 story in the last 7 days
The latest alchemab news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks alchemab across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

Cambridge biotech Alchemab Therapeutics extended its Series A with a £25 million investment from the British Business Bank, the state-owned lender's largest life sciences backing. The funding will grow its antibody database from 500 million to over a billion sequences and advance clinical candidates. The total Series A now stands at £109 million.
Summaries by ByteBrief